Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Sensorion S.A.. (1/25/17). "Press Release: Sensorion to Receive €950,000 from Bpifrance and the Occitania Region". Montpellier.

Region Region France
Organisations Organisation Sensorion S.A. (Euronext Alternext: ALSEN)
  Organisation 2 bpifrance
  Group France (govt)
Products Product high-content screening (HCS)
  Product 2 business development (state/region)
Index term Index term Sensorion–France (govt): credit, 201701– interest-free innovation loan (PTZI1) €950k from bpifrance + Occitania region
Persons Person Nguyen, Laurent (Sensorion 201701 CEO)
  Person 2 Maggos, Chris (LifeSci Advisors 201511 Managing Director Europe before Addex 201106–201302 BusDev + Communication)
     


> Non-dilutive financing, in the form of an interest-free innovation loan

> Proceeds to implement high content screening capacity


Sensorion (FR0012596468 – ALSEN), a biotechnology company specializing in the treatment of inner ear diseases, today announces that Bpifrance and the Occitania region of Southern France have selected to support the Company via a €950,000 interest-free innovation loan (PTZI1) after a competitive selection process.

Laurent Nguyen, CEO of Sensorion, commented: “I would like to thank our longstanding partner Bpifrance, and the Occitania region, for the confidence they have shown in Sensorion, a French company built on unique expertise in the field of inner-ear disorders. This latest funding will enable us to continue increasing our technological lead by developing an even more efficient screening platform for selecting relevant molecules and therapeutic targets to treat patients suffering from vertigo, hearing loss or tinnitus.”

The purpose of this funding is to strengthen the Sensorion preclinical platform by implementing High Content Screening (HCS) approaches, focused on discovering new drugs for inner-ear disorders.

Sensorion’s platform has already generated 3 first-in-class orally active drug candidates targeting inner-ear disorders:
> bouts of vertigo, with the SENS-111 compound (Phase 2);
> sudden sensorineural hearing loss, with the SENS-401 compound (Phase 1);
> ototoxicity, with the SENS-300 program (preclinical).

The HCS approach will add higher throughput phenotypic capacity for screening new molecules, and will enable further detailed studies of their properties and impact on new therapeutic targets in the inner ear.

???


About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drug candidates for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus. The first two programs are respectively in phase 1 (SENS-401) and phase 2 (SENS-111) clinical testing. Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion has been listed on the Euronext Alternext Paris exchange since April 2015.

www.sensorion-pharma.com


1 PTZI (Prêt à Taux Zéro pour l'Innovation): this interest-free innovation loan is specifically devoted to the development of Sensorion’s high-content screening platform and, pursuant to the terms, is repayable without interest from December 31, 2019.


Contacts

Sensorion
Laurent Nguyen
CEO
contact@sensorion-pharma.com Tel: +33 (0)4 67 20 77 30

Investor Relations, France
NewCap
Dusan Oresansky / Emmanuel Huynh
sensorion@newcap.eu
Tel: +33 (0)1 44 71 94 92

Investor Relations, Rest of the World
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
Tel.: +41 79 367 6254


Name: SENSORION
ISIN code: FR0012596468
Ticker: ALSEN


Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

   
Record changed: 2018-02-20

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top